Activity of clinafloxacin, trovafloxacin, quinupristin/dalfopristin, and other antimicrobial agents versus Staphylococcus aureus isolates with reduced susceptibility to vancomycin

Diagnostic Microbiology and Infectious Disease

Volumn 33, Issue 1, 1999, Pages 43-46

  Cohen, Michael A ^b   Huband, Michael D ^a  

^a PFIZER INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLINAFLOXACIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; GREPAFLOXACIN; IMIPENEM; LEVOFLOXACIN; OFLOXACIN; OXACILLIN; RIFAMPICIN; SPARFLOXACIN; TROVAFLOXACIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; NAPHTHYRIDINES; STAPHYLOCOCCUS AUREUS; VANCOMYCIN; VIRGINIAMYCIN;

EID: 0033011981     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(98)00121-7     Document Type: Article

References (21)

1. Centers for Disease Control and Prevention. (1997) Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin. MMWR 46:626-628, 635.
2. Cormican M.G., Jones R.N. Emerging resistance to antimicrobial agents in Gram-positive bacteria. Drugs. 51:(suppl 1):1996;6-12.
3. Daum M.G., Gupta M.G., Sabbagh R., Milewski W.M. Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin: isolation and purification of a constitutively produced protein associated with decreased susceptibility. J Infect Dis. 166:(suppl 1):1992;1066-1072.
4. Hiramatsu K., Aritaka N., Hanaki H., et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet. 350:1997;1670-1673.
5. Hiramatsu K. Reduced susceptibility of Staphylococcus aureus to vancomycin-Japan, 1996. MMWR. 46:1997;624-626.
6. Hiramatsu K., Hanaki H., Ino T., et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 40:1997;135-136.
7. Hiramatsu K. Update on vancomycin-resistant Staphylococcus aureus. Antibiotics Chemother. 1:1997;5.
8. Krcméry V. Jr, Hanzen J., Ciznar P., Brezaniova T. Vancomycin-resistant Staphylococcus aureus cellulitis in an immunocompromised child with Jobb's syndrome. Antibiotics Chemother. 1:1997;6.
9. Livermore DM, Warner M, Cookson BD. (1998) Detecting vancomycin-intermediate Staphylococcus aureus: Increased vigilance required by European microbiologists. Eurosurveillance Weekly Jan 8.
10. Martin R. Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1997. MMWR. 46:1997;765-766.
11. Martin R., Campbell C., Ellis H. Update Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1997 . MMWR. 46:1997;813-815.
12. Mlynarczyk G., Mlynarczyk A., Zabicka D., Jeljaszewicz J. Lysogenic conversion as a factor influencing the vancomycin tolerance phenomenon in Staphylococcus aureus. J Antimicrob Chemother. 40:1997;136-137.
13. Murray B.E. Minireview β-lactamase-producing enterococci . Antimicrob Agents Chemother. 36:1992;2355-2359.
14. National Committee for Clinical Laboratory Standards (1992) September Methods for determining bactericidal activity of antimicrobial agents, M26-T. Wayne, PA: NCCLS.
15. National Committee for Clinical Laboratory Standards (1997) January Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically-fourth edition; approved standard, M7-A4. Wayne, PA: NCCLS.
16. National Committee for Clinical Laboratory Standards (1998) January Performance standards for antimicrobial susceptibility testing; eighth informational supplement, M100-S8. Wayne, PA: NCCLS.
17. Noble W.C., Virani Z., Cree R.G.A. Co-transfer of vancomycin and other resistance genes from Enterococcus faecium. FEMS Microbiol Lett. 93:1992;195-198.
18. Robinson-Dunn B, Jennings G, Mitchell J. (1997) September 29, Characterization of a unique isolate of vancomycin-intermediate Staphylococcus aureus (VISA). Paper presented at: Thirty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario. Abstract LB-14.
19. Shonekan D., Handwerger S., Mildvan D. Comparative in-vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against Gram-positive bacteria. J Antimicrob Chemother. 39:1997;405-409.
20. Tenover F.C., Lancaster M.V., Hill B.C., et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol. 36:1998;1020-1027.
21. Voorn G.P., Kuyvenhoven J., Goessens W.H.F., et al. Role of tolerance in treatment and prophylaxis of experimental Staphylococcus aureus endocarditis with vancomycin, teicoplanin, and daptomycin. Antimicrob Agents Chemother. 38:1994;487-493.